In lieu of an abstract, here is a brief excerpt of the content:

Index Abbott, 195 ADD. See attention deficit disorder Adderall, 15, 102, 266, 299, 379. See also psychostimulants Adderall XR, 39 ADD Midwest (Ireland), 143, 145, 153 ADHD. See attention deficit–­ hyperactivity disorder ADHD Coaches Organ­ ization, 17, 21 ADHD coaching, 17, 21, 25 ADHD Eu­rope, 155–56, 233 Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (Argentina), 163, 174–75 adult ADHD, 13–14, 82, 248, 262, 270, 280, 386; awareness of, 48, 154, 280; coaching and, 25; nonreporting of, 39; practices related to, 87; prevalence rates for, 20. See also individual nation listings advocacy groups, 17, 20–22, 55, 123, 233, 380–82. See also individual nation listings Aedo, Cristián, 318 Ae-­Ngibise, K., 365 AFT Phar­ma­ceu­ti­cals, 303 Agence Nationale de la Sécurité des Medicaments (France), 239, 240, 249 Agência Nacional de Vigilância Sanitária (Brazil), 187, 190–92 Agenzia Italiana del Farmaco, 210, 212, 216 American Acad­ emy of Pediatrics, 24, 129 American Psychiatric Association, 1–2, 9. See also Diagnostic and Statistical Manual of Disorders Americans with Disabilities Act, 13 amphetamines, 10–11, 265. See also Adderall; methylphenidate; psychostimulants Anderson, Jessie, 292, 293 antidepressants, 170–72 anxiolytics, 170 Argentina, 4; ADHD definition in, 179; ADHD diagnosis in, 166, 167–68, 176, 178; ADHD’s emergence in, 162; ADHD treatment in, 169–76; analy­ sis in, of ADHD, 162–63, 167; DSM’s preeminence in, 179; health care in, 164–65, 169; ICD-10 in, 179; medicalization in, 164–65; methylphenidate in, 163, 166, 169–76, 180–81; neoliberalism in, 167; opposition in, to psychotropic medi­ cation, 175–76; phar­ma­ceu­ti­cal industry in, 167, 176–79, 181; psychoanalysis in, 165–66; social security sector in, 165; socio­ economics in, and ADHD, 169–70 Arizaga, M. Cecilia, 175 Associação Brasileira de Psiquiatria, 199–200, 201 Associação Brasileira de Saúde ­ Mental, 199, 200 Associação Brasileira do Deficit de Atenção, 194–95, 199 Associazione Italiana Famiglie ADHD, 209, 210, 211, 216, 222, 225 Astra-­Zeneca, 195 atomoxetine, 171, 173, 174, 176, 265–66, 294. See also psychostimulants attachment theory, 144 attention deficit disorder, 1–2, 12, 80 attention deficit–­ hyperactivity disorder: ac­cep­tance of, 48; adult, 1 (see also adult ADHD); advocacy groups and, 6, 17, 14, 380–82; aggression and, 276; age spectrum for, 386; alternative approaches to, 24–25, 35; be­ hav­ iors related to, 2, 6, 10, 108; blame and, 219–22, 224–25; Brazilian category for, 121; care models for, 124–27; challenges to, Page numbers in italics indicate figures and tables. 392  Index attention deficit–­ hyperactivity disorder (cont.) 6, 22–23, 65–66, 113–15, 322, 345–46, 382;­ children’s experiences of, 107–8, 272; citizen science and, 382; comorbidity and, 49, 100, 103, 168, 246–47, 248, 273, 362–63; confusion about, based on diagnostic translations, 121–22; as constructed social object, 224–25; context for, 2, 302, 327, 380–81; definition of, 246; depression and, 276; developmental disorders and, 274, 275; diagnosis of, 1–2, 17–19, 24, 87, 87–89, 290, 378 (see also individual nation listings); diagnostic migration and, 381–85; diagnostic threshold for, 378; diet and, 22; as disability, 13–16, 48–49, 61–62, 170, 341, 380–81; drugs for, 9, 15–17, 19–20, 379–80 (see also Adderall; atomoxetine; methylphenidate; psychostimulants); as dynamic pro­ cess, 119; early identification of, 386; ecological niche for, 356; educational accommodations for, 380; establishment of, 10–13, 377; etiology of, 11, 79, 80; ­ factors in, 216; false positives and, 302; ­ family physicians and, 41; ­future for, 23–26; gender and, 17, 19, 37–40, 83–84, 91, 149, 188, 248, 262, 273, 292, 325, 359, 386–87; globalization of, 3, 25–26, 377–79; “glocalization” of, 355; holistic approach to, 42, 44; vs. hyperkinetic disorder, 2–3; identity and, 155; international responses to, 3–6; Internet groups for, 383–84; label of, 69; as lifespan disorder, 1, 12–14, 129, 219, 386 (see also adult ADHD); management of, 21, 24–25; marketing and, 16–17, 26 (see also phar­ma­ceu­ti­cal industry); media coverage of, 114–15; medicalization of, 64, 78, 81, 85, 256, 333–35, 347–48; migration of, 382–85; mild, 69; as multifaceted prob­ lem, 130–31; multidisciplinary approach to, 82, 193 (see also multimodal treatment); national health care systems and, 379–80 (see also individual nation listings); as natu­ ral kind, 378; as neurodevelopmental disorder...

pdf

Additional Information

ISBN
9781421423807
Related ISBN
9781421423791
MARC Record
OCLC
1012344532
Pages
384
Launched on MUSE
2018-01-03
Language
English
Open Access
No
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.